The latter finding was somewhat unexpected because, at least in NSCLC, YAP/TEAD transcription factors have been shown to promote resistance to RAF- and MEK-targeted therapies via transcriptional upregulation of anti-apoptotic BCL2L1 (BCL2-like 1 or BCL-xL). The gene discussed is BCL2L1; the disease is non-small cell lung carcinoma.